Abstracts tagged "clinical trial"

Abstract Number: 0989 • ACR Convergence 2020
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial
Eliza Chakravarty¹, Tammy Utset², Diane Kamen³, Gabriel Contreras⁴, W. Joseph McCune⁵, Kenneth Kalunian⁶, Cynthia Aranow⁷, Megan Clowse⁸, Elena Massarotti⁹, Ellen Goldmuntz¹⁰, Jessica Springer¹⁰, Lynette Keyes-Elstein¹¹, Bill Barry¹¹, Ashley Pinckney¹¹ and Judith James¹², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Chicago, Chicago, IN, ³Medical University of South Carolina, Charleston, SC, ⁴University of Miami Miller School of Medicine, Miami, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷Feinstein Institutes for Medical Research, Manhasset, NY, ⁸Duke University, Chapel Hill, NC, ⁹Brigham and Women's hospital, Boston, MA, ¹⁰NIH/NIAID, Rockville, MD, ¹¹Rho, Durham, NC, ¹²Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE. However, it is associated…
Abstract Number: 1368 • ACR Convergence 2020
Proportions of Patients Achieving a Minimal Disease Activity State upon Treatment with Tildrakizumab in a Psoriatic Arthritis Phase 2b Study
Peter Nash¹, Michael Luggen², Ferran J. García Fructuoso³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Iain McInnes⁶, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²University Hospital/University of Cincinnati College of Medicine, Cincinnati Rheumatic Disease Study Group, Inc, Cincinnati, OH, ³Hospital CIMA Sanitas, Barcelona, Spain, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis.1 A randomized,…
Abstract Number: 1829 • ACR Convergence 2020
Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Richard Furie¹, Kenneth Kalunian², Joan Merrill³, Gabriel Abreu⁴ and Raj Tummala⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, ²School of Health Sciences, University of California, La Jolla, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg
Background/Purpose: In the randomized, double-blind, phase 2b MUSE trial, anifrolumab reduced disease activity vs placebo across multiple endpoints in patients with moderately to severely active…
Abstract Number: 0199 • ACR Convergence 2020
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
Edward C Keystone¹, Daniel Furst*², Jonathan Kay³, EunJin Choi⁴, Antonia Davidson⁵, YunJu Bae⁴, Darin Brimhall⁶, SangJoon Lee⁴, SungHyun Kim⁴ and DaHye Kwak⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celltrion, Inc., Incheon, Republic of Korea, ⁵PPD Development, Austin, TX, ⁶PPD Development, Las Vegas, NV
Background/Purpose: CT-P17 is a recombinant human monoclonal antibody that was developed as the first biosimilar adalimumab with high concentration (100 mg/mL) and citrate-free formulation. The…
Abstract Number: 0235 • ACR Convergence 2020
Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study
Lubna Abuqayyas¹, Laurence Cheng¹, Kyong Park¹, Marcia Teixeira dos Santos¹, Barbara Sullivan¹, Hui Wang¹, Yanchen Zhou¹, Vishala Chindalore², Stanley Cohen³, Alan Kivitz⁴, Maximilian Posch⁵ and Jane Parnes¹, ¹Amgen Inc., Thousand Oaks, CA, ²Pinnacle Research Group, Anniston, AL, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Charité Research Organisation, Berlin, Germany
Background/Purpose: B-cell activating factor (BAFF) and inducible costimulator ligand (ICOSL) are implicated in autoimmune disease pathogenesis, and clinical findings support their utility as drug targets…
Abstract Number: 0504 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Mark Genovese¹, Apinya Lertratanakul², Jaclyn K Anderson², Kim Papp³, William Tillett⁴, Filip Van den Bosch⁵, Shigeyoshi Tsuji⁶, Eva Dokoupilova⁷, Mauro Keiserman⁸, Xin Wang², Sheng Zhong², Patrick Zueger², Aileen Pangan⁹ and Philip Mease¹⁰, ¹Stanford University Medical Center, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL, ³Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁷Uherske Hradiste and University of Veterinary and Pharmaceutical Sciences,, Brno, Czech Republic, ⁸Pontificial Catholic University, Porto Alegre, Brazil, ⁹Abbvie Inc., La Grange, IL, ¹⁰Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment…
Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Richard Furie¹, Samir Parikh², Kenneth Harvey³, Christopher Kirk⁴, Darrin Bomba⁴ and MK Farmer⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²The Ohio State University, Columbus, OH, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc, San Francisco, CA, ⁵Kezar, Raleigh, NC
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
Abstract Number: 1039 • ACR Convergence 2020
Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis
Marcia Friedman¹, Stevens Janelle², Julianna Desmarais³, Daniel Seifer³, Brian Le³, Kimberly Ogle³, Christina Harrington³, Peter Jackson⁴, Dongseok Choi³ and James Rosenbaum³, ¹Oregon Health and Science University, Portland, OR, ²Tuality Healthcare, Hillsboro, OR, ³Oregon Health & Science University, Portland, OR, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
Abstract Number: 1369 • ACR Convergence 2020
Efficacy of Tildrakizumab in PsA: DAPSA Remission and Low Disease Activity in PASDAS Through Week 52
Saima Chohan¹, Arthur Kavanaugh², Vibeke Strand³, Richard Chou⁴, Alan Mendelsohn⁵, Stephen Rozzo⁵ and Philip Mease⁶, ¹Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ²UC San Diego Health System, San Diego, CA, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴University at Buffalo, School of Medicine and Biomedical Sciences, Amherst, NY, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Tildrakizumab (TIL), an anti–interleukin-23p19 monoclonal antibody, is approved in the US, EU, and Australia for treatment of moderate to severe plaque psoriasis. A randomized,…
Abstract Number: 1842 • ACR Convergence 2020
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
Anca Askanase¹, George Wan², Mary Panaccio², Enxu Zhao², Julie Zhu², Roman Bilyk² and Richard Furie³, ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].